RNA vs. SMMT, ITCI, MRNA, GMAB, RDY, VTRS, ASND, PCVX, QGEN, and ROIV
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Ascendis Pharma A/S (ASND), Vaxcyte (PCVX), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.
Avidity Biosciences vs.
Summit Therapeutics (NASDAQ:SMMT) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
Summit Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Summit Therapeutics' return on equity.
In the previous week, Summit Therapeutics had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 21 mentions for Summit Therapeutics and 20 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.71 beat Summit Therapeutics' score of 0.64 indicating that Avidity Biosciences is being referred to more favorably in the news media.
Avidity Biosciences has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.
4.6% of Summit Therapeutics shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summit Therapeutics received 141 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 69.01% of users gave Avidity Biosciences an outperform vote while only 58.56% of users gave Summit Therapeutics an outperform vote.
Summit Therapeutics has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Summit Therapeutics currently has a consensus price target of $35.44, suggesting a potential upside of 72.06%. Avidity Biosciences has a consensus price target of $66.69, suggesting a potential upside of 104.83%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Summit Therapeutics.
Summary
Avidity Biosciences beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:RNA) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy RNA Stock Free RNA Stock Alerts